Description General description A cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC50 = 0.01, 0.1, 3.9, and 3.8 µM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development in vivo. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC50 = 0.85, 0.047, 1.4, and 1.8 µM, respectively), as well as non-receptor TKs Lyn and Yes (IC50 = 4.3 and 5.8 µM, respectively). Packaging 5 mg in Plastic ampoule Packaged under inert gas Warning Toxicity: Harmful (C) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Godl, K., et al. 2005. Cancer Res.65, 6919. Laird, A.D., et al. 2002. FASEB J.16, 681. Krystal, G.W., et al. 2001. Cancer Res.61, 3660. Smolich, B.D., et al. 2001. Blood97, 1413. Laird, A.D., et al. 2000. Cancer Res.60, 4152. Shaheen, R.M., et al. 1999. Cancer Res.59, 5412. Sun, L. et al. 1999. J. Med. Chem.42, 5120.